title: Early CYFRA 21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients.
abstract: We have evaluated CYFRA 21-1 serum level variations as an indicator of tumor response and survival in 44 consecutive patients with locally advanced non-small cell lung cancer (NSCLC) treated with induction chemotherapy (IC). Irrespective of the initial CYFRA 21-1 serum concentration, a more than 65% decrease in the serum level after the first chemotherapy course was significantly predictive of an objective tumor response (p = 0.0022). In addition, a more than 80% decrease in this level significantly predicted a better disease-free survival (p = 0.039). In patients with initial CYFRA 21-1 serum levels > 3.3 ng/mL (n = 29), a more than 80% decrease after the first IC course was the most significant predictor of overall survival (p = 0.025) in a Cox analysis including initial staging, tumor response and surgery. We conclude that early monitoring of CYFRA 21-1 serum levels may be a useful prognostic tool for tumor response and survival in stage III NSCLC patients treated by induction chemotherapy.
authors.affiliation: Service de Pneumologie, CHU, Clermont-Ferrand, France.
authors.forename: P
authors.initials: P
authors.lastname: Merle
authors.forename: H
authors.initials: H
authors.lastname: Janicot
authors.forename: M
authors.initials: M
authors.lastname: Filaire
authors.forename: D
authors.initials: D
authors.lastname: Roux
authors.forename: C
authors.initials: C
authors.lastname: Bailly
authors.forename: C
authors.initials: C
authors.lastname: Vincent
authors.forename: F
authors.initials: F
authors.lastname: Gachon
authors.forename: A
authors.initials: A
authors.lastname: Tchirkov
authors.forename: F
authors.initials: F
authors.lastname: Kwiatkowski
authors.forename: A
authors.initials: A
authors.lastname: Naamé
authors.forename: G
authors.initials: G
authors.lastname: Escande
authors.forename: D
authors.initials: D
authors.lastname: Caillaud
authors.forename: P
authors.initials: P
authors.lastname: Verrelle
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood* / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012372:ROC Curve; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D053539:Keratin-19; C102012:antigen CYFRA21.1; D007633:Keratins